Please login to the form below

Not currently logged in
Email:
Password:

Icon appoints Allergan’s Ira Spector

He also has 17 years’ experience at Wyeth
icon ira spector

Dr Ira Spector has left his senior role at Allergan to join the clinical research organisation (CRO) Icon as executive VP, analytics and consulting.

Dr Spector was most recently senior VP of global development operations at Allergan where he spent four years. Prior to this he spent 17 years at Wyeth, leaving shortly after the company's takeover by Pfizer.

In his new role at Icon Dr Spector will lead the company's global consulting and drug development services and will also be responsible for Icon's business process improvement and analytics capabilities.

Icon's chief operating officer Dr Steve Cutler commented on the new appointment: “His extensive experience in managing some of the world's largest trials in areas such as oncology, vaccines and CNS, coupled with his expertise in using technology to drive innovation and process improvement, will enable us to provide further strategic input to our customers' drug and device programmes.”

10th September 2014

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
TRIDUCIVE

Hello we’re Triducive. We’re a healthcare strategy and value consultancy that provides expert and insight-driven solutions that strengthen and realise...

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...

Infographics